anxa2与tpa在肾透明细胞癌中的表达及临床意义word格式论文.docxVIP

目录中文摘要···········································································································1 英文摘要···········································································································4 英文缩写···········································································································8 研究论文 ANXA2 与 t-PA 在肾透明细胞癌中的表达及临床意义前言···········································································································9 材料与方法······························································································11 结果········································································································· 16 附图··········································································································17 附表········································································································ ·21 讨论··········································································································23 结论········································································································· 29参考文献································································································· 30 综述 ANXA2 及 t-PA 在肿瘤发生、发展中的作用·······································33 致谢················································································································· 46个人简历········································································································· 47ANXA2 与 t-PA 在肾透明细胞癌中的表达及临床意义摘要目的：肾细胞癌（RCC）的发病率居我国泌尿系恶性肿瘤的第二位， 仅次于膀胱癌，大约占成人全部恶性肿瘤的 2%-3%，其中最常见的病理 类型为肾透明细胞癌（RCCC）。肾细胞癌侵袭力较强，20%的患者初诊 时已发生转移，30%的患者术后发生转移。肾细胞癌的患者对放化疗均不 敏感。干扰素和白细胞介素-2 联合应用的传统免疫疗法亦不能显著提高 中、晚期患者的生存率。随着近些年对肾细胞癌侵袭机制研究的深入，分 子靶向治疗已成为肾细胞癌的有效治疗手段。有研究表明，ANXA2 和 t-PA 在多种肿瘤的发生、发展和浸润转移的过程中起重要作用，但有关联合检 测二者在肾透明细胞癌中的表达情况的研究，至今尚未有所报道。膜联蛋白 A2（ANXA2）是一类钙依赖性，并能够与膜磷脂结合的蛋 白质分子，在细胞骨架的稳定、吞噬和吞饮、DNA 合成、细胞增殖等方 面起着重要调节作用。ANXA2 的异常表达及分布变化与许多疾病有关， 如自身免疫性疾病、糖尿病、